Patients with severe aortic stenosis with peak velocity >4.0 m/sec, mean pressure gradient >40 mmHg, or aortic valve area <1.0 cm 2 were considered for valve replacement with TAVR. The indication to proceed with TAVR was determined at a multidisciplinary heart-valve team conference. Some patients with symptomatic heart failure received TAVR semi-urgently without the screening hospitalization; others received elective TAVR following the screening hospitalization. All patients received TAVR according to the standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, MN, USA) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach.
Evlolut pro
Manufactured by Medtronic
Sourced in United States
The Evolut PRO is a lab equipment product manufactured by Medtronic. It is designed to perform core functions, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
Automatically generated - may contain errors
4 protocols using evlolut pro
1
Severe Aortic Stenosis Management with TAVR
2
Transcatheter Aortic Valve Replacement Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients with severe aortic stenosis with peak velocity >4.0 m/s, mean pressure gradient >40 mmHg, or aortic valve area <1.0 cm2 were considered for TAVR after the multidisciplinary heart-valve team conference. All patients in this study met the indication for TAVR and agreed to receive TAVR after detailed informed consents from the patients and their relatives.
All patients received TAVR according to standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, Minnesota) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support. These procedural strategies were planned by the heart-valve team conference and finally determined by the attending cardiologists.
Clinical management after TAVR was provided by the attending cardiologists. Patients were generally discharged from index hospitalization following 1 week of careful observation for procedure-related complications. After the index discharge, patients were followed at our out-patient clinic or affiliated institutions by board-certified cardiologists. Anti-platelet regimens were at the discretion of the attending cardiologist according to patient comorbidities.
All patients received TAVR according to standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, Minnesota) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support. These procedural strategies were planned by the heart-valve team conference and finally determined by the attending cardiologists.
Clinical management after TAVR was provided by the attending cardiologists. Patients were generally discharged from index hospitalization following 1 week of careful observation for procedure-related complications. After the index discharge, patients were followed at our out-patient clinic or affiliated institutions by board-certified cardiologists. Anti-platelet regimens were at the discretion of the attending cardiologist according to patient comorbidities.
3
Transcatheter Aortic Valve Replacement for Severe Stenosis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients with severe aortic stenosis with max velocity > 4.0 m/s, mean pressure gradient > 40 mmHg, or aortic valve area < 1.0 cm2 were considered for TAVR in a multidisciplinary heart-valve team conference.
All patients received TAVR according to the standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, Minnesota) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support.
All patients received TAVR according to the standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, Minnesota) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support.
4
Transcatheter Aortic Valve Replacement Procedure
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients with severe aortic stenosis with max velocity > 4.0 m/s, mean pressure gradient > 40 mmHg, or aortic valve area < 1.0 cm [2 (link)] were considered for TAVR following a multidisciplinary heart-valve team conference. The prosthesis type, size, and approach site were determined on the basis of pre-procedural echocardiographic and multi-detector computed tomographic findings. The type of anesthesia was determined according to the patients’ comorbidities.
All patients received TAVR according to the standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, MN, USA) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support. An antithrombotic regimen was used at the discretion of the clinicians.
All patients received TAVR according to the standard procedure. Patients received self-expandable valves (Corevalve, Evolut R, Evlolut PRO, or Evolut PRO+; Medtronic plc., Minneapolis, MN, USA) or balloon-expandable valves (Sapien XT or Sapien 3; Edwards Lifesciences Inc., Irvine, CA, USA) via trans-femoral, trans-aorta, trans-subclavian, or direct aorta approach under general or local anesthesia support. An antithrombotic regimen was used at the discretion of the clinicians.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!